Phase Ib trial successfully completed

Based on the encouraging results of the first patients in the trial, the Medical and Scientific Advisory Board (“MSAB”) unanimously recommended the early termination of the study due to the primary and secondary endpoints having been achieved. The next step will be a Phase II trial to demonstrate efficacy.

More details can be found in the press release.